riluzole has been researched along with Scleroderma, Systemic in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a new drug representing the first active treatment for amyotrophic lateral sclerosis." | 1.30 | Acute hepatitis after riluzole administration. ( Blanc, P; Camu, W; Larrey, D; Ramos, J; Remy, AJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Remy, AJ | 1 |
| Camu, W | 1 |
| Ramos, J | 1 |
| Blanc, P | 1 |
| Larrey, D | 1 |
1 other study available for riluzole and Scleroderma, Systemic
| Article | Year |
|---|---|
Acute hepatitis after riluzole administration.
Topics: Acute Disease; Aged; Chemical and Drug Induced Liver Injury; Excitatory Amino Acid Antagonists; Fema | 1999 |